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Introduction {#sec1}
============

Platelet transfusion is an essential treatment for patients with thrombocytopenia ([@bib46], [@bib12]). The standard blood source for transfusion has been blood donors for many decades, and guidelines have been set to optimize transfusion conditions. However, this donation system requires large efforts to keep supply-demand balance due to the short shelf life of the platelet products (i.e., 4 days in Japan and 5 days in the United States), the anticipated absolute shortage in the near future in countries with aging societies, and the risk of blood-borne infection. Moreover, alloimmune platelet transfusion refractoriness (allo-PTR) is observed in approximately 5%--15% of patients who receive platelet transfusion, with the most dominant cause being the production of alloantibodies against human leukocyte antigen class I (HLA-I), which includes A, B, and C antigens ([@bib33], [@bib39], [@bib43]). In such HLA-I-mediated allo-PTR, transfused platelets are immediately rejected, except for HLA-I-compatible platelets. However, the need to select compatible donors limits the supply, with the most difficult cases being rare HLA-I types.

Human induced pluripotent stem cells (iPSCs) have been extensively studied as an *ex vivo* source for producing human cells and tissues ([@bib24]), and iPSC-derived platelets have the potential to resolve the aforementioned issues in current transfusion systems ([@bib45]). They can be produced without donor dependency and with good manufacturing practice from pathogen-free assured master cells devoid of blood-borne infections. As an expandable master cell source for platelets, we previously established immortalized megakaryocyte progenitor cell lines (imMKCLs) from human iPSCs, whereby the selectively qualified iPSC clone-derived imMKCLs can be prepared beforehand ([@bib32]). To create imMKCLs, in the megakaryocyte (MK)-lineage differentiation from iPSCs, three doxycycline (DOX)-inducible transgenes, *c-MYC*, *BCL-XL*, and *BMI1*, are introduced. In the presence of DOX, imMKCLs proliferate, whereas depletion of DOX from the culture medium leads to the maturation of imMKCLs to produce platelets (which we call iPLATs). We recently succeeded at producing the clinically required order of competent iPLATs by maturing imMKCLs under turbulent flow conditions consisting of optimal rages of turbulent energy and shear stress ([@bib23]). From the perspective of alloimmune compatibility, the ideal platelet product is autologous. Because iPSCs can be autologous, so too can iPLATs, but autologous products have high cost and are of variable quality. Therefore, the production of HLA-I homologous platelets as an off-the-shelf product from a clinically applicable iPSC library is under consideration ([@bib15], [@bib47]). However, due to high variability of the HLA-I gene, there is still a need to prepare a wide line-up of HLA-I types.

Platelets depleted of HLA-I can potentially be used as a universally effective transfusion measure for HLA-I-mediated allo-PTR. For depletion of HLA-I, genetic manipulation of the HLA-I complex molecule β2-microglobulin (B2M) has been shown to be effective ([@bib17], [@bib35], [@bib13]). The knockout procedure can completely deplete HLA-I expression for all A, B, C, and E antigens ("HLA-KO"), but this effect can also lead to the activation of human natural killer (NK) cells, which commit cytotoxic activity against cells downregulated of HLA-I ([@bib27], [@bib48], [@bib29]). Therefore, strategies to overexpress single-chain HLA-E fused with B2M ([@bib14]) or to disrupt HLA-A/B but retain HLA-C ([@bib51]) have been proposed. However, allo-PTR due to anti-HLA-C has been reported ([@bib39]). Furthermore, whether HLA-KO platelets activate NK cells remains unaddressed, including *in vivo* models with highly reconstituted human NK cells in circulation. In the present study, we produced HLA-KO iPLATs by knocking out *B2M* using the CRISPR/Cas9 method in our clinically applicable imMKCL system and evaluated their *in vitro* functionality and immunogenicity to NK cells. We also succeeded in establishing humanized mice with a high reconstitution of human NK cells by using MSTRG mice injected with interleukin-15 (IL-15) ligand and IL-15 receptor (Hu-NK-MSTRG mice) and assessed the circulation of HLA-KO iPLATs *in vivo*.

Results {#sec2}
=======

HLA-Null Platelets Were Successfully Produced from a β2-Microglobulin-Knockout imMKCL {#sec2.1}
-------------------------------------------------------------------------------------

To produce platelets without HLA-I expression, we sought to create HLA-I-depleted imMKCLs by knocking out the *B2M* gene. Because we did not succeed in genome editing the imMKCLs, we adopted the "re-reprogramming" method ([@bib41]), whereby imMKCLs are first reprogrammed to iPSCs (MK-iPSCs) and then subjected to B2M knockout using CRISPR/Cas9 technology ([Figures 1](#fig1){ref-type="fig"}A and 1B). Here, we used already established imMKCLs, which are highly proliferative and have high iPLAT production capacity, as the starting material, assuring the derivation of high-quality imMKCLs with the B2M-KO trait. These B2M-knockout MK-iPSCs bear the DOX-inducible *c-MYC*, *BCL-XL*, and *BMI1* transgenes of the original imMKCLs and were reinduced to imMKCLs (HLA-KO imMKCLs) and expanded in MK-differentiating medium including DOX ([Figure 1](#fig1){ref-type="fig"}A).Figure 1Production of HLA-KO iPLATs by Knocking Out β2-Microglobulin in imMKCL(A) Schema of the HLA-KO platelet production procedure. Knockout of β2-microglobulin (B2M) by CRISPR/Cas9 failed in imMKCL. Therefore, imMKCL was first re-reprogrammed to secondary iPSCs (MK-iPSC), in which B2M was knocked out. MK-iPSCs were then reinduced to imMKCL (HLA-KO imMKCL) in the presence of doxycycline (DOX) and, after expansion, matured to release iPLATs in DOX-OFF condition.(B) The targeting strategy of knocking out B2M by replacing exon 1 to a UBiC promoter-regulated puromycin-resistant gene for HLA-I nullification.(C--E) Flow-cytometry analysis of the generated CD41a^+^CD42b^+^ iPLATs and their yield (C), and the cell-surface expression of B2M (D) and of HLA-ABC and HLA-E (E) on imMKCLs, iPLATs, JRC platelets, and K562 cells. Gray histograms in (D) and (E) represent no staining control.(F) Clot retraction assay of iPLATs.WT, wild type; KO, HLA-KO; JRC, Japanese Red Cross; N.S., not significant. Data are representative of three independent experiments with error bars representing the mean ± SEM. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

The production of CD41a^+^CD42b^+^ iPLATs from HLA-KO imMKCLs was comparable with the wild-type (WT) counterpart ([Figure 1](#fig1){ref-type="fig"}C). HLA-KO iPLATs were confirmed to lack the surface expression of B2M and HLA-I molecules ([Figures 1](#fig1){ref-type="fig"}D and 1E). The cell-surface characteristics of HLA-KO iPLATs were comparable with those of WT iPLATs, donor platelets provided from the Japanese Red Cross Society (JRC), and peripheral blood platelets from healthy donors, as shown by the levels of human platelet antigens (HPAs) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). The cell size and ultrastructure of HLA-KO iPLATs were comparable with those of WT iPLATs ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C), which have a similar ultrastructure to JRC platelets but are slightly larger, as reported previously ([@bib23]). The *in vitro* functionality of HLA-KO iPLATs was also comparable, as shown by the low level of Annexin V binding and high level of hallmarks of *in vitro* platelet activation, namely, PAC-1 binding and CD62P expression upon stimulation ([Figures S1](#mmc1){ref-type="supplementary-material"}D--S1F). Finally, HLA-KO iPLATs and WT iPLATs were comparable for clotting ([Figure 1](#fig1){ref-type="fig"}F). These data indicate that the knockout procedure did not affect the production efficiency or function of iPLATs.

NK Cells Do Not Show Cytotoxic Response against iPLATs Regardless of HLA-I Expression {#sec2.2}
-------------------------------------------------------------------------------------

To assess whether iPLATs of HLA-KO phenotype preferentially elicit a cytotoxic response by NK cells, we performed co-culture assays *in vitro* ([Figure 2](#fig2){ref-type="fig"}A). NK cells separated from the peripheral blood mononuclear cells (PBMCs) of 11 healthy donors ([Table 1](#tbl1){ref-type="table"}) were each co-cultured with iPLATs for 6 h. The response of the NK cells was assessed by measuring the expression of CD107a, which reflects the release of cytotoxic granules from NK cells ([@bib2]). The expression of CD107a was highly enhanced against K562 cells, a typical positive control leukemic cell line used for cytotoxic assays, but just baseline level against WT and HLA-KO iPLATs ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A). We also tested the interferon-γ (IFN-γ) secretion from NK cells, finding the response, like CD107a, to be high against K562 cells, but baseline level against iPLATs ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Furthermore, Annexin V binding on iPLATs was not observed, suggesting no cellular damage to iPLATs ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Thus, the degranulation activity of NK cells was not induced by iPLATs regardless of HLA-I expression.Figure 2*In Vitro* Cytotoxic Assay of NK Cells Co-cultured with iPLATs or imMKCLs(A) Schema of the *in vitro* cytotoxic assay *in vitro*. NK cells and target cells were co-cultured with 1,000 U/mL human IL-2 for 6 h and then analyzed.(B) Flow-cytometry analysis of CD107a expression on NK cells from 11 healthy volunteers co-cultured with K562 cells, WT, or HLA-KO iPLATs. WT, wild type; KO, HLA-KO. Data are the mean ± SEM of three independent experiments.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.Table 1HLA Class I Profiles of the imMKCL and NK Cell Donors (A--K)HLA-AHLA-BHLA-CC1C2imMKCL02:0115:0102:02+02:0115:0103:03+A02:0140:0103:04+24:0215:0103:03+B02:0107:0203:04+33:0340:0107:02+C24:0207:0207:02+33:0358:0103:02+D11:0151:0115:02+24:0240:0203:04+E33:0344:0314:03+11:0115:0104:01+F02:0115:0104:01+26:0344:0308:01+G24:0239:0107:02+26:0335:0103:03+H24:0251:0101:02+31:0135:0103:03+I24:0254:0101:02+30:0156:0107:02+J11:0115:0104:01+31:0156:0107:02+K24:0215:0104:01+31:0135:0103:03+

iPLATs Do Not Express NK Cell-Activation Molecules {#sec2.3}
--------------------------------------------------

The balance between activation and inhibitory signals regulates NK cell activity ([@bib27], [@bib48], [@bib29]). Therefore, we compared the expression pattern of ligands for these signals on iPLATs. The major inhibitory ligands of NK cells, HLA-I molecules, suppress NK cell activation through killer cell immunoglobulin-like receptors (KIR). HLA-ABC was expressed on iPLATs without B2M knockout as well as on blood donor-derived platelets from the JRC, but not on B2M-knockout iPLATs, and had low expression on K562 cells ([Figure 1](#fig1){ref-type="fig"}E).

MIC-A, MIC-B, and ULBP family proteins are HLA-I-related molecules that are induced under stress situations such as virus infection, and act as activation ligands for NK cells ([@bib4], [@bib50]). The expression of MIC-A/B and ULBP proteins was not observed in any of the cells tested, except for ULBP-1 on K562 cells ([Figure 3](#fig3){ref-type="fig"}). Similarly, the DNAM-1 ligands CD112 and CD155 and NKp30 ligand B7H6, which are other activation ligands of NK cells ([@bib42], [@bib7], [@bib29], [@bib48]), were expressed on K562 cells but not on platelets ([Figure 3](#fig3){ref-type="fig"}). Other Nectin family proteins, including CD111 (nectin-1), CD113 (nectin-3) ([@bib30]), and CD48, a 2B4 ligand ([@bib31]), were not expressed ([Figure S3](#mmc1){ref-type="supplementary-material"}). Among the adhesion molecule intercellular adhesion molecule (ICAM) family proteins, which are ligands for LFA-1 on NK cells ([@bib3], [@bib29]), ICAM-2 was expressed in all cells, but not differently between platelets and K562 cells ([Figure 3](#fig3){ref-type="fig"}).Figure 3Platelets Do Not Express NK Cell-Activating MoleculesRepresentative histogram of the flow-cytometry analysis of HLA-I-related molecules, DNAM-1 ligands, B7H6 (NKp30 ligand), and ICAM family molecules for iPLATs, JRC platelets, and K562 cells. For iPLATs, both WT and HLA-KO types were analyzed. Gray histograms represent isotype control. WT, wild type; KO, HLA-KO. Data are representative of three independent experiments.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

The major inhibitory ligands are HLA-I, but there are other inhibitory ligands for NK cells. Cadherin family proteins are inhibitory ligands for KLRG1 receptor on NK cells ([@bib22]), but E-, N-, and R-cadherin were not expressed ([Figure S3](#mmc1){ref-type="supplementary-material"}). Additionally, PD-L1 and PD-L2 modulate NK cell activity through the receptor PD-1 ([@bib5]), and proliferating cell nuclear antigen (PCNA) and lectin-like transcript-1 (LLT1) modulate NK cell activity through NKp44 ([@bib38]) and NKR-P1A ([@bib37]), respectively. However, none of these ligands were expressed on platelets ([Figure S3](#mmc1){ref-type="supplementary-material"}). Therefore, while K562 cells may activate NK cells through ULBP-1, DNAM-1 ligands, and B7H6, platelets do not specifically express ligands that inhibit or activate NK cells.

HLA-KO iPLATs Can Circulate in Humanized Mice with Abundant Human NK Cells and Anti-HLA-I Antibodies {#sec2.4}
----------------------------------------------------------------------------------------------------

Next, we assessed whether HLA-KO iPLATs are rejected by NK cells *in vivo*. To generate mice with abundant human circulating NK cells, we transplanted MSTRG mice that express human macrophage colony-stimulating factor (M-CSF), thrombopoietin (TPO), and signal regulatory protein α (SIRPα) on *Rag*^*2*−/−^*Il2rg*^−/−^ background (to enhance human hematopoietic cell engraftment) ([@bib36], [@bib40]) with human CD34^+^ cells derived from cord blood, then intraperitoneally administered a human IL-15 and IL-15R-α mixture at 8 and 9 weeks to promote NK cell reconstitution ([Figure 4](#fig4){ref-type="fig"}A). By this method, MSTRG mice showed a high frequency of human NK cells in circulation, with the majority being CD56^dim^CD16^+^ mature NK cells (hereafter called Hu-NK-MSTRG mice; [Figures 4](#fig4){ref-type="fig"}B, 4C, and [S4](#mmc1){ref-type="supplementary-material"}A). NK cells separated from the spleen of Hu-NK-MSTRG mice showed CD107a upregulation when co-cultured with K562 cells but not with iPLATs ([Figure 4](#fig4){ref-type="fig"}D), indicating that the NK cells are competent for cytotoxic function. We further confirmed the *in vivo* functionality of human NK cells in the mice by infusing a mixture of WT and HLA-KO human iPSC-derived hematopoietic cells. The ratio of HLA-KO was lower in the lungs of Hu-NK-MSTRG mice than in non-humanized MSTRG mice, indicating that the NK cells are competent for cytotoxic function against HLA-deficient cells *in vivo* as well ([Figure S4](#mmc1){ref-type="supplementary-material"}B).Figure 4HLA-KO iPLATs Successfully Circulated in a Humanized Mouse Model with High NK Cell Reconstitution(A) Schema of the establishment of NK cell-reconstituted humanized mice (Hu-NK-MSTRG mice). Four-week-old MSTRG mice were transplanted with cord blood-derived human CD34^+^ cells. At 8 and 9 weeks old, the mice were intraperitoneally administered recombinant human IL-15 and IL-15 receptor α. At 10 weeks old, the mice were checked for the reconstitution of human hematopoietic cells and underwent transfusion experiments (n = 8).(B and C) Representative flow-cytometry scatterplots of circulating human blood cells in the mice (B) and the percentage of circulating human CD56^+^CD3^−^ cells (C) (n = 4).(D) Human NK cells were purified from Hu-NK-MSTRG mice and subjected to an *in vitro* cytotoxic assay against K562 cells and iPLATs. CD107a expression on NK cells was analyzed by flow cytometry (n = 3).(E and F) The number of total circulating hCD41a^+^CD42b^+^ iPLATs (E) and percentage of HLA-KO type among circulating iPLATs (F) in Hu-NK-MSTRG mice at pre-transfusion and 30 min, 3 h, and 6 h after transfusion (n = 8).(G) Schema of the allo-PTR model mice. Hu-NK-MSTRG mice were injected with mouse anti-HLA-A2 antibody 20 min prior to the transfusion of iPLATs.(H) The percentage of HLA-KO type among circulating iPLATs in Hu-NK-MSTRG mice treated with anti-HLA-A2 antibody (allo-PTR mice) or the isotype control at pre-transfusion and 30 min, 3 h, and 6 h after transfusion (n = 3 or 4 in each group).WT, wild type; KO, HLA-KO. Data are representative of three or more independent experiments with error bars representing the mean ± SEM. ^∗^p \< 0.05 and ^∗∗^p \< 0.01. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To assess the circulation capacity of HLA-KO iPLATs, we transfused a mixture of WT and HLA-KO iPLATs labeled with TAMRA dye to Hu-NK-MSTRG mice and compared the ratio between the WT and HLA-KO types in the blood circulation at various time points ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Circulation of the transfused iPLATs was observed up to 6 h post transfusion ([Figure 4](#fig4){ref-type="fig"}E). Importantly, the ratio of HLA-KO was stable from pre-injection to up to 6 h ([Figure 4](#fig4){ref-type="fig"}F). This result indicates that HLA-KO iPLATs have the same circulating capability as WT iPLATs even in the presence of human NK cells.

In a separate experiment, 20 min prior to the transfusion of iPLATs, mouse anti-HLA-A2 antibody was injected into Hu-NK-MSTRG mice to create an HLA-I-mediated allo-PTR model ([@bib17]) ([Figure 4](#fig4){ref-type="fig"}G). Similar to the kinetics in patients with anti-HLA-I antibody-mediated allo-PTR transfused with incompatible donor-derived platelets, the circulation of HLA-WT iPLATs was less at 30-min transfusion, and only HLA-KO iPLATs were essentially observed after 3 h ([Figures 4](#fig4){ref-type="fig"}G, 4H, and [S4](#mmc1){ref-type="supplementary-material"}D). These data suggest that HLA-KO iPLATs are an effective source for alloimmune PTR, which is mostly mediated by anti-HLA-I antibodies.

Discussion {#sec3}
==========

We have recently proposed a clinically applicable system to produce transfusion-relevant numbers of iPLATs from imMKCLs by using a turbulent flow-based bioreactor and adding an aryl hydrocarbon receptor antagonist and Rho-associated protein kinase inhibitor for imMKCL maturation and iPLAT release ([@bib23]). iPLATs produced in this system have shown comparable function with blood donor-derived platelets and are devoid of tumorigenicity upon irradiation, a precaution also taken for usual transfusion products to eliminate the risk of transfusion-related graft-versus-host disease. Based on this system, this study shows that HLA-KO iPLATs were successfully produced from HLA-KO imMKCLs ([Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}), and further found the unique property of HLA-KO iPLATs to evade NK cell-mediated and anti-HLA-I antibody-mediated immune responses from *in vitro* and *in vivo* assays ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [S2--S4](#mmc1){ref-type="supplementary-material"}). Thus, a functional, safe, and universal HLA-I iPLAT product can be supplied, resolving the risk of compatible-donor shortage in HLA-I-mediated allo-PTR. Because one HLA-KO iPLAT line can be applied for all HLA-I types, the cost will be significantly lower than had we prepared autologous iPLATs or a wide line-up of iPLATs with various HLA-I types from an iPSC library ([@bib15], [@bib47]).

The nullification of HLA-I on platelets has been achieved before by knocking out or knocking down *B2M* to enable platelets to evade anti-HLA-I alloresponses ([@bib17], [@bib13], [@bib6]). While the gene knockout procedure is capable of achieving complete deletion of the HLA-I expression, it may not inhibit the activation of NK cells through the HLA-I receptor, KIR, thus leading to rejection of the allografts ([@bib21]). A short hairpin RNA (shRNA)-based mRNA knockdown procedure was reported to leave a low expression level of HLA-I, which has the potential advantage of suppressing the NK cell response against HLA-I nullified cells ([@bib49]). Other approaches to evade NK cell response include the overexpression of single-chain HLA-E fused with B2M ([@bib14]), knockout of the *HLA-A* and *HLA-B* loci while retaining *HLA-C* ([@bib51]), and the overexpression of CD47 ([@bib10]). However, it has not been addressed whether platelets nullified with all HLA-I molecules elicit an NK cell response, and thus it remains unknown which approach is most suitable. In our current study, we found that platelets do not elicit cytotoxic responses by NK cells even when HLA-I is completely depleted ([Figures 2](#fig2){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}). Our data show that the lack of NK cell-activating receptor ligands such as DNAM-1 ligands and the NKp30 ligand B7H6 on iPLATs may be partly involved in this effect ([Figures 3](#fig3){ref-type="fig"} and [S3](#mmc1){ref-type="supplementary-material"}).

We also looked into various ligands and adhesion molecules that could affect NK cell activation, such as non-DNAM-1 ligand Nectin family molecules, including Nectin-1 and Nectin-3, ICAM family proteins, which are ligands for LFA-1 on NK cells ([@bib3], [@bib29]), CD48, which binds 2B4 receptor for activation ([@bib31]), and cadherins, which bind KLRG1 receptor to inhibit NK function via ITAM (immunoreceptor tyrosine-based activation) signaling ([@bib22], [@bib28]) and also have a functional role in aggregation and thrombus formation ([@bib11]). Other inhibitory ligands, such as LLT1, PD-L1, PD-L2, and PCNA ([@bib1], [@bib37], [@bib5], [@bib34], [@bib38]), were also analyzed. However, we did not find a specific lack of activating molecules or specific expression of inhibitory molecules on the platelets. We speculate that the inert response may depend on the non-nuclear properties of platelets, since erythrocytes, which are also anucleate and do not express HLA-I, are not attacked by NK cells, except in specific circumstances such as *Plasmodium* infection ([@bib8]). Further studies are required, but elucidating how iPLATs evade NK cells could contribute to understanding other immune phenomena such as tumor immune evasion.

For *in vivo* evaluation, we adopted MSTRG mice transplanted with human cord blood cells ([Figures 4](#fig4){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}). MSTRG mice have an enhanced reconstitution of human hematopoiesis by knocking in genes encoding human M-CSF, TPO, and SIRPα into the *Rag2*^−/−^*Il2rg*^−/−^ background ([@bib36], [@bib40]). By further injecting a mixture of human IL-15 ligand and receptor, as previously reported ([@bib20]), we succeeded in establishing "Hu-NK-MSTRG" mice, which reconstituted high levels of human NK cells. Our data showed that the reconstituted human NK cells in Hu-NK-MSTRG mice have cytotoxic activity similar to that of NK cells in human peripheral blood ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}B). We further set up an allo-PTR model by injecting mouse anti-HLA antibody. HLA-KO iPLAT transfusion to this model suggested that HLA-KO iPLATs could circulate upon transfusion to human subjects, including allo-PTR patients with anti-HLA-I alloantibodies. Several groups have previously reported the establishment of humanized mice with a high reconstitution of NK cells and have tested the *in vivo* NK cell functionality ([@bib44], [@bib26], [@bib36], [@bib25], [@bib19]). However, these reports show the *in vivo* rejection of only tumorigenic HLA-deficient cells, while this report showed this in non-tumor HLA-deficient cells, thus providing a pre-clinical model for HLA-depleted cell therapies. Moreover, there are no reports on platelet circulation in humanized mice with a high reconstitution of NK cells and anti-HLA-I antibodies.

There has been a debate about whether platelets capture circulating B2M to express functional HLA-I ([@bib16]). With regard to our model, although human blood cells that express B2M were in circulation, we did not observe a difference in the ratio of HLA-KO and WT iPLATs, and their HLA expression level remained unchanged during the assessment. Based on these observations, we conclude that iPLATs do not readily upregulate HLA-I expression through the adoption of circulating B2M.

The production of anti-HPA alloantibodies is the second major cause of allo-PTR and also a primary cause of fetal/neonatal alloimmune thrombocytopenia and post-transfusion purpura. However, HPA knockout is not appropriate due to the existence of antibody-recognition sites on crucial functional platelet molecules, such as CD61 (ITGB3), CD41 (ITGA2B), CD42b, CD36, and CD29 ([@bib9], [@bib18]). As such, HPA conversion using the CRISPR/Cas9 system has been proposed ([@bib52]). Considering that a substantial portion of patients with anti-HPA antibodies also carry anti-HLA-I antibody, HLA-KO iPLATs may be an ideal platform for further gene editing of HPA.

In conclusion, our study shows a proof of concept that HLA-KO iPLATs can be used as universal HLA-I-type platelets. This study should lead to the clinical application of HLA-KO iPLATs for resolving the shortage risk of HLA-I-compatible donors in allo-PTR conditions and contribute to the cost reduction of iPLATs. In addition, we also found that the unique non-immunogenic property of HLA-depleted platelets does not activate NK cells. Owing to their capacity to evade alloimmune responses and their safe and uniform product profile by sterile production from quality-assured imMKCL master cells, HLA-KO iPLATs may also lead to new standardized platelet-based therapies such as injection for tissue regeneration and drug-delivery systems.

Experimental Procedures {#sec4}
=======================

Study Approval {#sec4.1}
--------------

Donor-derived human platelets were provided by the JRC. Human platelets were used in compliance with the Guidelines on the Use of Donated Blood in R&D from the Ministry of Health, Labour and Welfare of Japan. The collection and usage of peripheral blood from healthy volunteers, the collection of cord blood from healthy volunteers, and animal experiments were approved by the Ethical Committee of Kyoto University and Kumamoto University. All experiments using human samples were conducted in accordance with the Declaration of Helsinki.

Cell Culture {#sec4.2}
------------

imMKCLs were established from human iPSCs as previously reported ([@bib32]). imMKCLs were cultured in IMDM medium (Sigma) with L-glutamine (25030-081; Thermo Fisher Scientific), Insulin-transferrin-selenium (41400-045; Thermo Fisher), 50 μg/mL ascorbic acid (A4544; Sigma-Aldrich), and 450 μM 1-thioglycerol (M6145; Sigma-Aldrich). DOX-ON proliferation condition: imMKCLs were cultured with 15% fetal bovine serum (FBS), 50 ng/mL recombinant human thrombopoietin (rhTPO: PeproTech), 50 ng/mL recombinant human stem cell factor (rhSCF: R&D Systems), and 5 μg/mL DOX-inducible transgenes (c*-MYC*, *BIM1*, and *BCL-XL*). DOX-OFF production of iPLATs condition: the medium contained 10% human plasma (Cosmo Bio \#12250210, Japan Blood Products Organization), 10 U heparin sodium (\#(01)14987476163428; Yoshido), 50 ng/mL rhSCF, 200 ng/mL TA-316 (Nissan Chemical), 15 μM KP-457 (Kaken Pharmaceutical), 0.5 μM GNF-351 (Calbiochem), and 0.5 μM Y39983 (MedChemExpress). imMKCLs were cultured with this medium for 6 days in 125- or 250-mL Corning Erlenmeyer cell-culture flasks (\#431143 and \#431144; Sigma-Aldrich) in shaking conditions using Lab-Therm shakers (Kuhner) ([@bib23]).

MK-iPSCs were established from imMKCLs by re-reprogramming ([@bib41]) and cultured with the mouse C3H10T1/2 cell line in DMEM F-12 medium (Sigma) with MEM non-essential amino acids solution (100×) (11140050; Thermo Fisher), penicillin-streptomycin-glutamine (100×) (10378016; Thermo Fisher), 20% KnockOut Serum Replacement (10828028; Thermo Fisher), 0.1 mM 2-mercaptoethanol (Sigma), and 5 ng/mL basic fibroblast growth factor (R&D Systems).

K562 cells were cultured with RPMI-1640 medium (Sigma), 10% FBS, and 100× penicillin-streptomycin-glutamine (10378016; Thermo Fisher).

Establishment of a β2-Microglobulin-Knockout imMKCL {#sec4.3}
---------------------------------------------------

Exon 1 of *B2M* was selected as the knockout target. The sequence for homologous recombination was constructed as 5′-arms-loxP-Ubic-Puro^r^-loxP-3′-arms. The sequence of the 5′-arm was Fw 5′-TGG CGG CCG CTC TAG ACC CTT TGT CTT CCA GTG TCT-3′, and Rv 5′-ATT ATA CGA AGT TAT GCC CGC ATG CTG TCA GCT TCA GGA ATG-3′; and the 3′-arm was Fw 5′-ATA CGA AGT TAT GCA ACA GGG TTT CAC CGT GTT AG-3′, and Rv 5′-GCT TGA TAT CGA ATT CGA GGC ACA GTA CAT CTT GGA-3′. This cassette was integrated into pBluescript KS(+) vector using In-Fusion reaction to construct the targeting vector plasmid. The single-guide RNA (sgRNA) expression vector was designed as Guide Fw 5′-TCA TGC CAT CCG TAA GAT GC-3′ and Guide Rv 5′-CTA AAA CTA GCT GTG CTC GC-3′, and inserted into pHL-H1-ccdB-mEF1a-RiH vector using In-Fusion reaction to construct the sgRNA expression vector pHL-H1-B2M-sgRNA-mEF1a-RiH.

MK-iPSC line \#11 (MKiPS\#11) was established from imMKCLs by re-reprogramming ([@bib41]). imMKCLs at the DOX-ON proliferation stage were transfected with an episomal vector carrying reprogramming factors (*OCT3/4* with shRNA of *TP53*, *SOX2*, *KLF4*, and *MYCL*) by using Human Stem Cell Nucleofecto Kit 2 (VPH-5022; Lonza). The transfected imMKCLs were co-cultured with the C3H10T1/2 cell line as feeder cells for 3--4 weeks. iPSC-like colonies were picked up as MK-iPSCs. For gene manipulation, MKiPS\#11 was placed into feeder-free culture condition: iMatrix-511 (892012; MTR)-coated dishes in StemFit AK03N medium (Ajinomoto, Tokyo, Japan). For establishment of B2M-KO imMKCL, the sgRNA expression vector, the targeting vector, and the CRISPR/Cas9 expression vector (pHL-UbicP-SphcCas9-iP-A) were transfected into 0.8 × 10^6^ MK-iPSCs by electroporation. MK-iPSCs were cultured with 10 μM Y27632 (Wako) for 1 day and selected with 1 μg/mL puromycin from day 3. Seven days after the electroporation, individual colonies were picked. After genotyping each clone by using PCR primer 1, 5′-ACG AAA TGG CGG CAC CTT AT-3′, primer 2, 5′-CCC GTC CTA AAA TGT CCT TC-3′, primer 3, 5′-CTG CAA GAA CTC TTC CTC AC-3′, and primer 4, 5′-TGG CGC CAT GAT AGC TCA AA-3′, an adequately targeted clone was selected (HLA-KO MK-iPSCs). HLA-KO MK-iPSCs were placed into the C3H10T1/2 cell co-culture condition. For differentiation to imMKCLs, HLA-KO MK-iPSCs were cultured by the Sac method ([@bib32]). HLA-KO MK-iPSCs were cultured in differentiation medium from day 0 to day 14. After day 14, HLA-KO hematopoietic progenitor cells were collected from the Sac-like structure and cultured in imMKCL medium with 50 ng/mL rhSCF, 50 ng/mL rhTPO, and 5 μg/mL DOX. The DOX-induced transgenes were expressed, and HLA-KO imMKCLs were obtained.

Flow Cytometry {#sec4.4}
--------------

The following antibodies were used: from BD Biosciences, hCD42b-APC (clone HIP1: 551061), HLA-ABC-FITC (clone G46--2.6: 557348), β2-microglobulin-FITC (clone TU99; 551338), hCD3-FITC (clone SP34: 556611), hCD56-PerCP/Cy5.5 (clone B159: 560842), hCD107a-BV421 (clone H4A3: 562623), and hCD49b-PE (clone 12F1: 555669); from R&D systems, ULBP-1-PE (clone 170818; FAB1380P), ULBP-2/5/6-APC (clone 165903; FAB1298A), ULBP-3-PE (clone 166510; FAB1517P), hOCIL/CLEC2d(LLT1)-APC (clone 402659; FAB3480A), and B7H6-PE (clone 875001; FAB7144P); from BioLegend, hCD41a-APC (clone HIP8; 303710), hCD42b-PE (clone HIP1; 303906), hCD112-PE (clone TX31; 337409), hCD155-APC (clone SKII.4; 337617), MIC-A/B-PE (clone 6D4; 320906), HLA-E-PE (clone 3D12; 342603), ICAM-1-Pacific Blue (clone HA58; 353109), ICAM-2-PE (clone CBR-IC2/2; 328505), ICAM-3-APC (clone CBR-IC3/1; 330011), hCD19-APC/Cy7 (clone HIB19; 302218), hCD45-PE/Cy7 (clone HI30; 304016), hCD3-FITC (clone UCHT1; 300406), mCD45.2-PE (clone 104; 109808), hCD56-BV421 (clone HCD56; 318328), hCD16-BV510 (clone 3G8; 560918), hCD324 (E-Cadherin)-APC (clone 67A4; 324107), hCD36-APC/Cy7 (clone 5-271; 336213), hCD29-PE (clone TS2/16; 303003), hCD109-PE (clone W7C5; 323305), hCD61-FITC (clone VI-PL2; 336403), PD-L1-PE (clone 29E.2A3; 329705), PD-L2-PE (clone 24F.10C12; 329605), hCD48-PE (clone BJ40; 336707), h/m/rPCNA-PE (clone PC10; 307908), and hCD111-PE (clone R1.302; 340404); from eBioscience, hCD33-APC (clone WM-53; 17-0338-41) and hCD41a-efluor 450 (clone HIP8; 48-0419-42); from Santa Cruz Biotechnology, N/R-cadherin-Alexa Fluor 647 (clone H-4; sc-271386) and hCD42c-PE (clone F-11; sc-377129 PE); and from MBL International, hCD113-Alexa Fluor 488 (clone N3.12.4; K0224-A48).

For staining, cells were incubated with antibodies in PBS(−) (Sigma) with 3% FBS for 30 min at 4°C, except platelets at room temperature. The data were obtained with a FACS Verse, FACS Aria IIIu, or FACS Canto II (BD Biosciences), and analyzed by FlowJo 10.4 (FlowJo).

Clot Retraction Assay {#sec4.5}
---------------------

iPLATs were suspended in IMDM medium with 20% human plasma. iPLATs were then mixed with 2 U/mL thrombin and incubated at 37°C for 2 h ([@bib53]).

NK Cell Co-culture Assay {#sec4.6}
------------------------

PBMCs were isolated from whole blood by density gradient centrifugation using Ficoll-Paque PREMIUM (GE Healthcare) from healthy volunteers. PBMCs were incubated with CD4, CD14, and CD19 MicroBeads (130-045-101, 130-050-201, 130-050-301; Miltenyi Biotec) at 4°C for 30 min. After washing, MACS Columns (Miltenyi Biotec) were used for the isolation. A mixture of CD4^+^, CD14^+^, and CD19^+^ cells was used as negative control cells. CD4-CD14-CD19 cells were incubated with CD3 and CD8 MicroBeads (130-050-101, 130-045-201; Miltenyi Biotec) at 4°C for 30 min, and cells negatively separated by MACS columns were used as the NK cell population. For the CD107a expression assay, 1 × 10^6^ cells/mL human NK cells were co-cultured with target cells at an E/T ratio of 1:1 in 200 μL of RPMI-1640 medium with 10% pooled human serum (inactivated) (12181450; Cosmo Bio), 2 mM L-glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin (basal medium) with 1,000 U/mL recombinant human IL-2, and 1/200 volume of CD107a-BV421 for 6 h at 37°C in a 5% CO~2~ incubator in a 96-well plate. After incubation, the plate was centrifuged, and each well was resuspended in 100 μL of PBS with 2% FBS with anti-CD56-PerCP-Cy5.5 and anti-CD3-FITC antibodies. After 30-min incubation, the samples were analyzed by flow cytometry. The cytotoxic activities of NK cells were evaluated by measuring CD107a expression and normalized as follows: relative value of CD107a = (CD107a positive \[%\] of NK cells with target cells)/(CD107a positive \[%\] of NK cells alone). For Annexin V binding of the target cells, the E/T ratio was 8:1, 4:1, or 0.25:1 in basal medium with 1,000 U/mL recombinant human IL-2. K562 cells were labeled by the CellTrace CFSE Cell Proliferation Kit (Thermo Fisher Scientific). After incubation, the plate was centrifuged, and each well was resuspended in PBS(−) with 10× Binding Buffer (556454; BD Biosciences), Annexin V, and antibodies for hCD41a and hCD42b. After 30-min incubation, the samples were analyzed by flow cytometry.

Mouse Model {#sec4.7}
-----------

Human CD34^+^ cells (1 × 10^6^) were isolated from human cord blood using the CD34^+^ Cell Isolation Kit (Miltenyi Biotec) and intravenously injected into MSTRG (*CSF1*^h/h^ *SIRPA*^tg^ *THPO*^h/h^ *Rag2*^−/−^ *Il2rg*^−/−^) mice irradiated with 2.5 Gy at 6 weeks old. Four weeks after the transplantation, the reconstitution of human cells was confirmed by flow-cytometric analysis. Recombinant human IL-15 (0.5 μg) (\#200-15; PeproTech) and 1.0 μg of recombinant human IL-15 R alpha Fc chimera protein (\#7195-IR-050; RSD) in 200 μL of PBS were intraperitoneally injected at days 0, 3, 7, and 14 at 4 weeks post transplantation. The reconstitution of human NK cells was confirmed by flow-cytometric analysis. For the allo-PTR mouse model, 3 μg/body weight (g) of anti-HLA-A2 immunoglobulin G (\#0131HA; One Lambda) in 100 μL of PBS was injected into Hu-NK-MSTRG mice 20 min before platelet transfusion.

Human NK Cell Isolation from Mouse Spleen {#sec4.8}
-----------------------------------------

The spleens of mice were minced and filtered through 40-μm cell strainers to make single-cell suspensions. The suspensions were treated with ammonium-chloride-potassium lysis buffer to lyse erythrocytes. CD56-positive NK cells were then isolated using anti-hCD56 microbeads (\#130-050-401; Miltenyi Biotec) and positively selected through LS columns (\#130-122-729; Miltenyi Biotec).

Transfusion Assay {#sec4.9}
-----------------

For the platelet analysis, WT and HLA-KO iPLATs were mixed and labeled with 5′-TAMRA (C6121; Thermo Fisher Scientific). iPLATs (5--8 × 10^7^ in 100 μL of bicarbonate buffer) were intravenously injected into the mice. Blood samples (10 μL) were collected at 30 min, 3 h, and 6 h after the transfusion.

Statistical Analysis {#sec4.10}
--------------------

All data are presented as means ± SEM and were analyzed by GraphPad Prism 5 (GraphPad Software). Statistically significant differences were determined by one-way ANOVA, Tukey-Kramer test for multiple comparisons, and two-tailed t test for pairwise comparisons. p values are indicated in the figures as ^∗^p \< 0.05 and ^∗∗^p \< 0.01.
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